BACKGROUND: Linezolid is recommended for treatment of pneumonia and other invasive infections caused by methicillin-resistant Staphylococcus aureus (MRSA). The premise underlying this recommendation is that linezolid inhibits in vivo production of potent staphylococcal exotoxins, including Panton-Valentine leukocidin (PVL) and α-hemolysin (Hla), although supporting evidence is lacking. METHODS: A rabbit model of necrotizing pneumonia using MRSA clone USA300 was used to compare therapeutic effects of linezolid (50 mg/kg 3 times/day) and vancomycin (30 mg/kg 2 times/day) administered 1.5, 4, and 9 hours after infection on host survival outcomes and in vivo bacterial toxin production. RESULTS: Mortality rates were 100% for untreated rabbits and 83%-100% for vancomycin-treated rabbits. In contrast, mortality rates were 25%, 50%, and 100% for rabbits treated with linezolid 1.5, 4, and 9 hours after infection, respectively. Compared with untreated and vancomycin-treated rabbits, improved survival of rabbits treated 1.5 hours after infection with linezolid was associated with a significant decrease in bacterial counts, suppressed bacterial production of PVL and Hla, and reduced production of the neutrophil-chemoattractant interleukin 8 in the lungs. CONCLUSIONS: Across the study interval, only early treatment with linezolid resulted in significant suppression of exotoxin synthesis and improved survival outcomes in a rabbit model of MRSA necrotizing pneumonia.
BACKGROUND:Linezolid is recommended for treatment of pneumonia and other invasive infections caused by methicillin-resistant Staphylococcus aureus (MRSA). The premise underlying this recommendation is that linezolid inhibits in vivo production of potent staphylococcal exotoxins, including Panton-Valentine leukocidin (PVL) and α-hemolysin (Hla), although supporting evidence is lacking. METHODS: A rabbit model of necrotizing pneumonia using MRSA clone USA300 was used to compare therapeutic effects of linezolid (50 mg/kg 3 times/day) and vancomycin (30 mg/kg 2 times/day) administered 1.5, 4, and 9 hours after infection on host survival outcomes and in vivo bacterial toxin production. RESULTS: Mortality rates were 100% for untreated rabbits and 83%-100% for vancomycin-treated rabbits. In contrast, mortality rates were 25%, 50%, and 100% for rabbits treated with linezolid 1.5, 4, and 9 hours after infection, respectively. Compared with untreated and vancomycin-treated rabbits, improved survival of rabbits treated 1.5 hours after infection with linezolid was associated with a significant decrease in bacterial counts, suppressed bacterial production of PVL and Hla, and reduced production of the neutrophil-chemoattractant interleukin 8 in the lungs. CONCLUSIONS: Across the study interval, only early treatment with linezolid resulted in significant suppression of exotoxin synthesis and improved survival outcomes in a rabbit model of MRSA necrotizing pneumonia.
Authors: Timothy F Jones; C Buddy Creech; Paul Erwin; Susan G Baird; Amy M Woron; William Schaffner Journal: Clin Infect Dis Date: 2006-03-30 Impact factor: 9.079
Authors: John S Francis; Meg C Doherty; Uri Lopatin; Cecilia P Johnston; Gita Sinha; Tracy Ross; Mian Cai; Nadia N Hansel; Trish Perl; John R Ticehurst; Karen Carroll; David L Thomas; Eric Nuermberger; John G Bartlett Journal: Clin Infect Dis Date: 2004-12-07 Impact factor: 9.079
Authors: Loren G Miller; Francoise Perdreau-Remington; Gunter Rieg; Sheherbano Mehdi; Josh Perlroth; Arnold S Bayer; Angela W Tang; Tieu O Phung; Brad Spellberg Journal: N Engl J Med Date: 2005-04-07 Impact factor: 91.245
Authors: Blanca E Gonzalez; Kristina G Hulten; Megan K Dishop; Linda B Lamberth; Wendy A Hammerman; Edward O Mason; Sheldon L Kaplan Journal: Clin Infect Dis Date: 2005-07-29 Impact factor: 9.079
Authors: Iram Enayet; Ali Nazeri; Leonard B Johnson; Kathleen Riederer; Joan Pawlak; Louis D Saravolatz Journal: Clin Infect Dis Date: 2006-02-28 Impact factor: 9.079
Authors: Vien T M Le; Hoan N Le; Marcos Gabriel Pinheiro; Kenneth J Hahn; Mary L Dinh; Kajal B Larson; Shawn D Flanagan; Cedric Badiou; Gerard Lina; Christine Tkaczyk; Bret R Sellman; Binh An Diep Journal: Antimicrob Agents Chemother Date: 2017-03-24 Impact factor: 5.191
Authors: Binh An Diep; Vien T M Le; Zehra C Visram; Harald Rouha; Lukas Stulik; Etyene Castro Dip; Gábor Nagy; Eszter Nagy Journal: Antimicrob Agents Chemother Date: 2016-09-23 Impact factor: 5.191
Authors: Avanish K Varshney; Xiaobo Wang; Jennifer MacIntyre; Richard S Zollner; Kerry Kelleher; Oleg V Kovalenko; Ximo Pechuan; Fergus R Byrne; Bettina C Fries Journal: J Infect Dis Date: 2014-05-05 Impact factor: 5.226
Authors: L Hua; J J Hilliard; Y Shi; C Tkaczyk; L I Cheng; X Yu; V Datta; S Ren; H Feng; R Zinsou; A Keller; T O'Day; Q Du; L Cheng; M Damschroder; G Robbie; J Suzich; C K Stover; B R Sellman Journal: Antimicrob Agents Chemother Date: 2013-12-02 Impact factor: 5.191